SuperworthFulcrum Therapeutics shares outstanding FULC
Diluted shares outstanding, averaged over each quarter, from 2018.
- Latest quarter, to Jun 30, 2026
- 76.3M
- On a year earlier
- +21.9%
- more shares
Fulcrum Therapeutics had 76.3M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 21.9% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 65.8M | +7% |
| FY2024 | 61.3M | −1% |
| FY2023 | 61.9M | +19% |
| FY2022 | 52.1M | +28% |
| FY2021 | 40.6M | +47% |
| FY2020 | 27.5M | +22% |
| FY2019 | 22.7M | +1426% |
| FY2018 | 1.5M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 76.3M | +22% | |
| Q1 FY26 | 76.2M | +22% | |
| Q4 FY25 | 65.8M | +7% | |
| Q3 FY25 | 62.6M | +0% | |
| Q2 FY25 | 62.5M | −2% | |
| Q1 FY25 | 62.5M | +1% | |
| Q4 FY24 | 61.3M | −1% | |
| Q3 FY24 | 62.4M | +1% | |
| Q2 FY24 | 63.6M | +3% | |
| Q1 FY24 | 62M | +4% | |
| Q4 FY23 | 61.9M | +19% | |
| Q3 FY23 | 61.8M | +34% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Fulcrum Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.